Grettchen FS

Language: Spanish
References: 18
Page: 37-44
PDF size: 474.12 Kb.

ABSTRACT

Introduction: Atopic dermatitis is the most prevalent cutaneous disease worldwide, it belongs to the group of disorders with common characteristics of allergenic sensitization, epithelial barrier anomalies and type 2 immune responses. Objective: To investigate the main genetic and epigenetic factors in the pathogenesis of this disease. Results: Different investigations have shown that atopic dermatitis is a disease with high heritability and heterogeneous clinical phenotypes, which is precisely justified by genetic mechanisms associated with the reciprocity of immunological and epidermal effects, influenced by epigenetic factors. The strongest known genetic risk factor is the presence of null mutations in FLG, however, mutations of this gene are neither necessary nor sufficient. Discussion: Gene therapy for the treatment of atopic dermatitis, although it has been postulated, should be considered with caution, because the monoclonal antibodies do not constitute with the current degree of knowledge a definitive solution, given all the mechanisms involved and the different expressions of the illness. In this context, the concepts of bioethics and genetic counseling acquire relevance. Conclusions: Although from the point of view of the forensic sciences, the description of specific genetic alterations in a person or group of people can allow their genetic identification or biological filiation to a group; also for the forensic doctor the possible development of specific therapy that can vary the prognosis of disabling chronic pathologies could be associated to the concepts of “exhaustion of the therapeutic resource” and “judicialization of medicine”.

REFERENCES

1. Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z. Molecular Genetic of Atopic dermatitis: An Update. Int J Health Sci (Qassim). 2016; 10(1):96- 120.

2. Bin L, Leung DY. Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma Clin Immunol. 2016; 12:52. DOI 10.1186/s13223-016-0158-5

3. Brown S. Molecular mechanisms in atopic eczema: insight gained from genetic studies. J Pathol. 2017; 241 (2): 140–145. doi:10.1002/path.4810

4. Esparza-Gordillo J, Matanovic A, Marenholz I, Bauerfeind A, Rohde K, Nemat K, et al. Maternal Filaggrin Mutations Increase the Risk of Atopic Dermatitis in Children: An Effect Independent of Mutation Inheritance. PLoS Genet. 2015; 11(3): e1005076. doi: 10.1371/journal.pgen.1005076

5. Filipowska-Grońska A, Weryńska-Kalemba M, Bożek A. Filipowska B, Zebracka-Gala J, Rusinek D, et al. The frequency of polymorphic variants of filaggrin gene and clinical atopic dermatitis. Adv Dermatol Allergol. 2016;33(1):37-41. doi: 10.5114/pdia.2015.48036

6. Liang Y, Chang C, Lu Q. The Genetics and Epigenetics of Atopic Dermatitis—Filaggrin and Other Polymorphisms. Clinic Rev Allerg Immunol. 2016; 51(3):315-328. DOI 10.1007/s12016-015-8508-5

7. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023):1109-1122. doi: 10.1016/S0140- 6736(15)00149-X

8. Gonçalo M. Deficiency in barrier function and slow barrier recovery in atopic dermatitis does not depend only on the FLG mutation status. BJD. 2015; 172:1475. DOI: 10.1111/bjd.13836

9. Sullivan M, Silverberg NB. Current and Emerging Concepts in Atopic Dermatitis Pathogenesis. Clin Dermatol. 2017, 35 (4): 349-353. doi: 10.1016/j. clindermatol.2017.03.006

10. Kim JE; Kim JS; Cho DH, Park HJ. Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis. Int J Mol Sci. 2016; 17, 1234

11. Kasemsarn P, Bosco J, Nixon RL. The Role of the Skin Barrier in Occupational Skin. Curr Probl Dermatol. 2016; 49:135-143. doi: 10.1159/000441589)

12. Ma CA, Stinson JR, Zhang Y, Abbott Weinreich MA, Hauk PJ, Reynolds PR, et al. Germline hypomorphic CARD11 mutations in severe atopic disease. Nat Genet. 2017; 49(8):1192-1201. doi: 10.1038/ng.3898

13. Leitch CS, Natafji E, Yu C, abdul-Ghaffar S, Madarasingha N, Venables ZC, et al. Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells. J Allergy Clin Immunol. 2016; 138(2): 482–490.e7. doi: 10.1016/j.jaci.2015.11.040

14. Thyssen JP, Tang L, Husemoen LL, Stender S, Szecsi PB, Menné T, et al. Filaggrin gene mutations are not associated with food and aeroallergen sensitization without concomitant atopic dermatitis in adults. J Allergy Clin Immunol. 2015 May;135(5):1375-8.e1. doi: 10.1016/j.jaci.2015.01.001

15. Saldanha SN, Royston KJ, Udayakumar N, Tollefsbol TO. Epigenetic Regulation of Epidermal Stem Cell Biomarker and Their Role in Wound Healing. Int J Mol Sci. 2016; 17(1): 16. doi: 10.3390/ijms17010016

16. Kezic S, Jakasa I. Filaggrin and Skin Barrier Function. Curr Probl Dermatol. 2016; 49: 1–7. DOI: 10.1159/000441539

17. Park KY, Li K, Seok J, Seo SJ. An Analysis of the Filaggrin Gene Polymorphism in Korean Atopic Dermatitis Patients. J Korean Med Sci. 2016; 31(7):1136- 1142. doi:10.3346/jkms.2016.31.7.1136

18. Thomsen SF, Elmose C, Szecsi PB, Stender S, Kyvik KO, Backer V, et al. Filaggrin gene loss-of-function mutations explain discordance of atopic dermatitis within dizygotic twin pairs. Int J Dermatol. 2016; 55(12):1341-1344. doi: 10.1111/ijd.13401